Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Return on Capital Employed: 2022-2025

Historic Return on Capital Employed for bioAffinity Technologies (BIAF) over the last 3 years, with Sep 2025 value amounting to -1.79%.

  • bioAffinity Technologies' Return on Capital Employed rose 24.00% to -1.79% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.79%, marking a year-over-year increase of 24.00%. This contributed to the annual value of -2.10% for FY2024, which is 110.00% down from last year.
  • Per bioAffinity Technologies' latest filing, its Return on Capital Employed stood at -1.79% for Q3 2025, which was up 54.36% from -3.93% recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Return on Capital Employed high stood at -0.33% for Q4 2022, and its period low was -3.93% during Q2 2025.
  • For the 3-year period, bioAffinity Technologies' Return on Capital Employed averaged around -1.85%, with its median value being -1.72% (2024).
  • Over the last 5 years, bioAffinity Technologies' Return on Capital Employed had its largest YoY gain of 24bps in 2025, and its largest YoY loss of 237bps in 2025.
  • bioAffinity Technologies' Return on Capital Employed (Quarterly) stood at -0.33% in 2022, then tumbled by 81bps to -1.15% in 2023, then crashed by 147bps to -2.61% in 2024, then grew by 24bps to -1.79% in 2025.
  • Its Return on Capital Employed stands at -1.79% for Q3 2025, versus -3.93% for Q2 2025 and -3.68% for Q1 2025.